Contributions
Abstract: P999
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 16 Microbiology and Virology
Background: Viruses have been associated with the etiopathogenesis of multiple sclerosis (MS); among them, human herpesvirus 6 (HHV-6) has accumulated some of the most compelling evidence associated with it. Furthermore, recent studies suggest that other HHV, cytomegalovirus (CMV), has an intriguing relation with MS and a protective effect has been proposed.
Objective: To analyze HHV-6 and CMV IgG and IgM antibodies prevalence in MS patients and healthy controls (HC).
Methods: A total of 245 MS patients (63.7% female, mean age 38 years, mean starting age 28 years) and 75 HC (65.3% female, mean age 37 years) were included in this cross-sectional retrospective study. An ELISA assay was performed to detect HHV-6 IgG and IgM antibodies (Vidia) and CMV IgG and IgM antibodies (Vircell) in their serum samples. Antibody titers were expressed as artificial units (AU=10*sample absorbance/cut-off value; AU>11=positive, AU< 9=negative).
Results:
A.) Prevalence: 1. HHV-6: 1.1). MS patients: 93.0% (23.2 AU) for IgG and 5.7% for IgM antibodies (4.2 AU); 1.2) HC: 89.3% (24.2 AU) for IgG and 4.0% (4.5 AU) for IgM antibodies (p=0.297; OR=1.59). 2. CMV: 2.1) MS patients: 59.8% (15.9 AU) for IgG and 1.7% for IgM antibodies (3.0 AU); 2.2) HC: 60.0% (17.4 AU) for IgG and 0% for IgM antibodies (p=0.980; OR=1.01). 3. HHV-6 IgG regarding CMV IgG: 3.1) MS patients: 96.9% among CMV IgG negative vs. 89.0% among CMV IgG positive (p=0.012; OR=5.6); 3.2) HC: 90.0% among CMV IgG negative vs. 88.9% among CMV IgG positive (p=0.917; OR=1.1). 4. CMV IgG regarding HHV-6 IgG: 4.1) MS patients: 88.2% among HHV-6 IgG negative vs. 58.5% among HHV-6 IgG positive (p=0.013; OR=5.5); 4.2) HC: 62.5% among HHV-6 IgG negative vs. 59.7% among HHV-6 IgG positive (p=0.878; OR=1.1).
B.) Age stratification: 1. HHV-6 IgG prevalence: 1.1) MS patients: 94.7% when < 30 years vs. 87.2% if >45 years (p=0.026; O.R.=2.6); 1.2) HC: 100% when < 30 years vs. 89.5% if >45 years (p=0.119). 2. CMV IgG prevalence: 2.1) MS patients: 48.6% when < 30 years vs. 72.9% if >45 years (p=0.016; O.R.=2.8); 2.2) HC: 45.5% when < 30 years vs. 68.4% if >45 years (p=0.139; O.R.=2.6).
Conclusion. An intriguing inverse correlation between HHV-6 and CMV IgG antibody prevalence in MS patients but not in HC has been found. Furthermore, an inverse relation to the age has been also described; possible associations with immunosenescence and the appearance of progressive forms in MS should be further studied.
Disclosure:
M.I. Dominguez-Mozo: nothing to disclose.
S. Perez-Perez: nothing to disclose.
I. Ortega-Madueño: nothing to disclose.
M.A. Garcia-Martinez: nothing to disclose.
L. Costa-Frossard: received payment for lecturing or travel expenses from Sanofi-Genzyme, Merck, Biogen, Novartis, Teva.
L.M. Villar: received payment for lecturing, travel expenses or research grants from Sanofi-Genzyme, Merck, Biogen, Novartis, Teva, Binding Site.
J.C. Alvarez-Cermeño: received payment for lecturing, travel expenses or research grants from Sanofi-Genzyme, Merck, Biogen, Novartis, Teva.
R. Arroyo: received honoraria for speaking and participating as investigators in clinical trials and non-financial support from Merck-Serono, Teva, Sanofi-Aventis, Genzyme, Novartis, Biogen Idec, Roche and Bayer-Schering.
R. Alvarez-Lafuente: Reports grants and personal fees from Merck Serono, personal fees and non-financial support from Biogen IDEC, grants, personal fees and non-financial support from Novartis Pharmaceuticals S.A., grants and personal fees from Genzyme, non-financial support from TEVA Pharma, S.L., non-financial support from Roche.
Abstract: P999
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 16 Microbiology and Virology
Background: Viruses have been associated with the etiopathogenesis of multiple sclerosis (MS); among them, human herpesvirus 6 (HHV-6) has accumulated some of the most compelling evidence associated with it. Furthermore, recent studies suggest that other HHV, cytomegalovirus (CMV), has an intriguing relation with MS and a protective effect has been proposed.
Objective: To analyze HHV-6 and CMV IgG and IgM antibodies prevalence in MS patients and healthy controls (HC).
Methods: A total of 245 MS patients (63.7% female, mean age 38 years, mean starting age 28 years) and 75 HC (65.3% female, mean age 37 years) were included in this cross-sectional retrospective study. An ELISA assay was performed to detect HHV-6 IgG and IgM antibodies (Vidia) and CMV IgG and IgM antibodies (Vircell) in their serum samples. Antibody titers were expressed as artificial units (AU=10*sample absorbance/cut-off value; AU>11=positive, AU< 9=negative).
Results:
A.) Prevalence: 1. HHV-6: 1.1). MS patients: 93.0% (23.2 AU) for IgG and 5.7% for IgM antibodies (4.2 AU); 1.2) HC: 89.3% (24.2 AU) for IgG and 4.0% (4.5 AU) for IgM antibodies (p=0.297; OR=1.59). 2. CMV: 2.1) MS patients: 59.8% (15.9 AU) for IgG and 1.7% for IgM antibodies (3.0 AU); 2.2) HC: 60.0% (17.4 AU) for IgG and 0% for IgM antibodies (p=0.980; OR=1.01). 3. HHV-6 IgG regarding CMV IgG: 3.1) MS patients: 96.9% among CMV IgG negative vs. 89.0% among CMV IgG positive (p=0.012; OR=5.6); 3.2) HC: 90.0% among CMV IgG negative vs. 88.9% among CMV IgG positive (p=0.917; OR=1.1). 4. CMV IgG regarding HHV-6 IgG: 4.1) MS patients: 88.2% among HHV-6 IgG negative vs. 58.5% among HHV-6 IgG positive (p=0.013; OR=5.5); 4.2) HC: 62.5% among HHV-6 IgG negative vs. 59.7% among HHV-6 IgG positive (p=0.878; OR=1.1).
B.) Age stratification: 1. HHV-6 IgG prevalence: 1.1) MS patients: 94.7% when < 30 years vs. 87.2% if >45 years (p=0.026; O.R.=2.6); 1.2) HC: 100% when < 30 years vs. 89.5% if >45 years (p=0.119). 2. CMV IgG prevalence: 2.1) MS patients: 48.6% when < 30 years vs. 72.9% if >45 years (p=0.016; O.R.=2.8); 2.2) HC: 45.5% when < 30 years vs. 68.4% if >45 years (p=0.139; O.R.=2.6).
Conclusion. An intriguing inverse correlation between HHV-6 and CMV IgG antibody prevalence in MS patients but not in HC has been found. Furthermore, an inverse relation to the age has been also described; possible associations with immunosenescence and the appearance of progressive forms in MS should be further studied.
Disclosure:
M.I. Dominguez-Mozo: nothing to disclose.
S. Perez-Perez: nothing to disclose.
I. Ortega-Madueño: nothing to disclose.
M.A. Garcia-Martinez: nothing to disclose.
L. Costa-Frossard: received payment for lecturing or travel expenses from Sanofi-Genzyme, Merck, Biogen, Novartis, Teva.
L.M. Villar: received payment for lecturing, travel expenses or research grants from Sanofi-Genzyme, Merck, Biogen, Novartis, Teva, Binding Site.
J.C. Alvarez-Cermeño: received payment for lecturing, travel expenses or research grants from Sanofi-Genzyme, Merck, Biogen, Novartis, Teva.
R. Arroyo: received honoraria for speaking and participating as investigators in clinical trials and non-financial support from Merck-Serono, Teva, Sanofi-Aventis, Genzyme, Novartis, Biogen Idec, Roche and Bayer-Schering.
R. Alvarez-Lafuente: Reports grants and personal fees from Merck Serono, personal fees and non-financial support from Biogen IDEC, grants, personal fees and non-financial support from Novartis Pharmaceuticals S.A., grants and personal fees from Genzyme, non-financial support from TEVA Pharma, S.L., non-financial support from Roche.